The gene expression signature of each drug must be open source
Just when the world had started to appear normal with the return of man-made disasters to the center of the scene, the (most predictable) rise of the Omicron variant of SARS-CoV-2 (B.1.1.529 ) reminded us that we may now be entering the Age of Pandemics.
It seems our petty politics and foolish desire to make money have made us over-funneling ourselves with antibiotics, gene expression inhibitors, and vaccines – in general biology and in the ecology of the planet – so, clearly, the turnaround time is here.
As Life on Earth is now joining forces to kick us off its list, it is time that we too unite and see if we can pass our age of ignorance and survive long enough to become wiser and join the harmonics of the world. planet.
It’s an hour to prove that we are a species and our USP is our ability to cooperate. But, unfortunately, we live in the age of IPRs.
One of the biggest problems with modern science is that it has now become a source of wealth instead of knowledge and hence knowledge has become property.
If a cure is found for an illness, it is now more important not to reveal your secret to others, even if it results in the deaths of a million people. As every scientific breakthrough is worth a billion dollars, now we have everyone working in a vacuum and fighting for IPRs.
The current scientific research environment is possibly the worst time to have a rapidly evolving pandemic that requires a global collective effort devoid of selfish personal agendas.
Since we are unlikely to let go of our selfishness anytime soon, the only way out is to EMERGENCY recognize the borders where open global collaboration is possible without upsetting the basket of apples of the rich who run the planet, and first on this list. could be drug discovery.
The fastest way to deploy a drug is reuse – that is, using an old drug known to be otherwise safe for humans to cure a new disease.
If we look at our fight against the coronavirus pandemic, most of what we used was repurposed drugs and, even if they healed or not, they gave people hope which is extremely critical in a healing process.
If we take a look at new tools that aid in the rapid deployment of a reused drug, matching a drug’s gene expression signature to a virus is a very useful shortcut.
If you are a layman like me, this concept is based on the idea that every chemical / molecule, whether it is a drug or a virus that a cell is subjected to, causes some of the genes to s ‘express more (positive regulation) and others to express themselves. less (downregulate) than their “normal” expression. This information is summarized as the gene phrase “signature” and, as common sense suggests, a drug with a signature opposite to that of a pathogen will have a good chance of preventing the pathogen from causing problems.
The way forward, ideally, is to have a global consensus that when a pandemic is officially declared all IPRs are instantly suspended, but now it is too much against the greedy species that we have become, I therefore suggests a limited action plan.
All the nations of the world are already almost united in how drugs are approved for human use (because there is money to be made), so it is a little easier to add one more condition to the process, that is, each drug must have its gene expression signature identified and recorded.
If we have such a global repository of signatures for all drugs, we will be much better prepared to reuse a drug quickly by deploying global intellectual resources in the matching process.
This idea may meet with resistance among the new morality where money before life is an accepted saying, but there is a business case for open source gene expression signature data.
If a drug is protected by IPR, the owner will gain a lot if the drug is reused for a new disease and therefore, even if the new relationship is identified by a third party, there is obviously money to be made by the original. drug discoverer.
This solution has shortcomings because there is no benefit for a scientist to find a new relationship between a new pathogen and an old drug, so some flattening is required, but it should be possible as if there were l money there is always a long way to go.
Even if the lucrative deal is not resolved, we will still have a better chance of identifying a reusable drug because, I hope there are still people on the planet who will work mercilessly to find drugs to save lives.
The opinions expressed above are those of the author.
END OF ARTICLE